Orosomucoid 2 maintains hepatic lipid homeostasis through suppression of de novo lipogenesis
The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is caused by imbalance in lipid metabolism. In this study, we show that the hepatokine orosomucoid (ORM) 2 is a key regulator of de novo lipogenesis in the liver. Hepatic and plasma ORM2 levels are markedly decreased in obese murine models and patients with NAFLD. Through multiple loss- and gain-of function studies, we demonstrate that ORM2 is essential to maintain hepatic and systemic lipid homeostasis. At the mechanistic level, ORM2 binds to inositol 1, 4, 5-trisphosphate receptor type 2 to activate AMP-activated protein kinase signaling, thereby inhibiting sterol regulatory element binding protein 1c-mediated lipogenic gene program. Notably, intraperitoneal injections of recombinant ORM2 protein or stabilized ORM2-FC fusion protein markedly improved liver steatosis, steatohepatitis and atherosclerosis in preclinical mouse models, without adverse effects on body weight or food intake. Thus, these findings suggest that ORM2 may serve as a potential target for therapeutic intervention in NAFLD, non-alcoholic steatohepatitis and related lipid disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In those studies, ORM2 was shown to protect hepatocytes from steatosis while increasing portal inflammation in murine in vivo and in vitro models.”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · doi:10.1038/s41423-025-01313-7 · cites this paper as [63]
Citations
Cites
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Watterson, K. R., Bestow, D., Gallagher, J., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2013) · Neurosignals · doi:10.1159/000334144 · Cited by 3,389
Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications
Fabbrini, E., Sullivan, S., & Klein, S. (2010) · Hepatology · doi:10.1002/hep.23280 · Cited by 2,100
The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950
Li, Y., Xu, S., Mihaylova, M. M., Zheng, B., Hou, X., Jiang, B., Park, O., Luo, Z., Lefai, E., Shyy, J. Y.-J., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.03.009 · Cited by 1,778
LKB1 is the upstream kinase in the AMP-activated protein kinase cascade
Woods, A., Johnstone, S. R., Dickerson, K., Leiper, F. C., Fryer, L. G. D., Neumann, D., Schlattner, U., Wallimann, T., Carlson, M., & Carling, D. (2003) · Current Biology · doi:10.1016/j.cub.2003.10.031 · Cited by 1,650
Hawley, S. A., Pan, D. A., Mustard, K. J., Ross, L., Bain, J., Edelman, A. M., Frenguelli, B. G., & Hardie, D. G. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.05.009 · Cited by 1,589
Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.003 · Cited by 1,504
Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495
Woods, A., Dickerson, K., Heath, R., Hong, S.-P., Momcilovic, M., Johnstone, S. R., Carlson, M., & Carling, D. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.06.005 · Cited by 1,392
Cited by
Physiological and pathological roles of lipogenesis
Jeon, Y. G., Kim, Y. Y., Lee, G., & Kim, J. B. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00786-y · Cited by 243
(2025) · doi:10.1038/s41423-025-01313-7 · Cited by 97
“Similarly, ORM2 levels in the livers and plasma of patients with MASLD as well as in MASH model mice are lower than those in the corresponding controls [62, 63].”
Sun, C., Zhang, J., Hou, J., Hui, M., Qi, H., Lei, T., Zhang, X., Zhao, L., & Du, H. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114005 · Cited by 76
Advances and perspectives in fluorescent probes for imaging hepatopathy-related biomarkers
Quan, W., Song, W., Zhang, Q. Y., Huang, H., & Lin, W. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2023.215407 · Cited by 65
Amelioration of nonalcoholic fatty liver disease by inhibiting the deubiquitylating enzyme RPN11
Zhou, B., Luo, Y., Bi, H., Zhang, N., Ma, M., Dong, Z., Ji, N., Zhang, S., Wang, X., Liu, Y., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.07.014 · Cited by 60
Self-citation
Metadata
- Authors
- Zhou, B., Luo, Y., Ji, N., Hu, C., & Lu, Y.
- Affiliations
- Shanghai Medical College of Fudan University (CN)
- Shanghai Jiao Tong University (CN)
- Fudan University (CN)
- Venue
- Nature Metabolism
- Published
- 2022-09-01
- Volume
- 4
- Issue
- 9
- Pages
- 1185-1201
- ISSN
- 2522-5812 (ISSN-L)
- OpenAlex
- W4294053472
- Cited by
- 75
- References
- 66
- Citations by year
- 2026: 18 · 2025: 20 · 2024: 22 · 2023: 13 · 2022: 2
- FWCI
- 10.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- ORM2, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, hepatic lipid homeostasis, de novo lipogenesis, AMPK signaling, SREBP-1c, hepatic steatosis, atherosclerosis, hepatokines, obesity
- MeSH terms
- Animals, Homeostasis, Inositol, Lipids, Orosomucoid, Lipogenesis, Mice, Sterol Regulatory Element Binding Protein 1, AMP-Activated Protein Kinases, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Orosomucoid 2 maintains hepatic lipid homeostasis through suppression of de novo lipogenesis. https://app.cochat.ai/papers/10.1038/s42255-022-00627-4
- The paper
- Zhou, B., Luo, Y., Ji, N., Hu, C., & Lu, Y. (2022). Orosomucoid 2 maintains hepatic lipid homeostasis through suppression of de novo lipogenesis. Nature Metabolism. https://doi.org/10.1038/s42255-022-00627-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.